UC-Davis: Evaluation of a novel anticancer agent in tumor bearing dogs to define its pharmacokinetic profile and biological activity:COTCO18

Species: Canines
Tumor: Mammary Carcinoma, Melanoma, Squamous Cell Carcinoma, or Soft Tissue Sarcoma
For more information: please visit “http://www.vetmed.ucdavis.edu/ccc/clinical_trials/index.cfm”

Purpose of Study: This clinical trial is led by the National Cancer Institute (NCI) and conducted through the Comparative Oncology Trials Consortium.
A clinical trial of a novel anticancer agent in tumor bearing dogs with either melanoma, soft tissue sarcoma, squamous cell carcinoma or mammary carcinoma intended to define biological changes in tumor and surrogate tissues following drug exposure that may elucidate mechanisms of action and potential biomarkers of its activity. The study period is 21 days.
Costs associated with this study will be provided during the dog’s participation. In the event there are any complications arising during the study period the dog’s management will be covered by study funds. This would include any unanticipated hospitalizations at the patient’s Veterinary Teaching Hospita